Axiom Biosciences intends to pursue an IPO on the Hong Kong Stock Exchange (HKEX) followed by a co-listing on the Nasdaq—a strategy the company claims it’s the first U.S. biotech to use.
Axiom Biosciences intends to pursue an IPO on the Hong Kong Stock Exchange (HKEX) followed by a co-listing on the Nasdaq—a strategy the company claims it’s the first U.S. biotech to use.
